• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Henry Schein CEO Stanley M. Bergman to retire

Henry Schein CEO Stanley M. Bergman to retire

July 15, 2025 By Sean Whooley

A portrait of Henry Schein CEO Stanley Bergman
Stanley M. Bergman. [Image courtesy of Henry Schein]

Henry Schein (Nasdaq: HSIC) announced today that Stanley M. Bergman intends to retire as CEO at the end of the year.

Bergman has had a 45-year tenure at Henry Schein, with more than 35 years spent in the corner office. He plans to continue leading the company as CEO until his retirement and to remain as chair thereafter.

Henry Schein said it is commencing a formal search process in conjunction with a nationally recognized executive search firm. It intends to consider internal and external candidates.

“With the progress made advancing our BOLD+1 strategic plan and with strong management in place, it is the right time for me to retire at the end of the year,” Bergman said in a news release. “I look forward to working with the board to identify my successor and effect a smooth transition. Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the company’s future.”

Philip A. Laskawy, lead director for Henry Schein added the company became a global leader in dental and medical products under Bergman’s stewardship.

“We owe a tremendous debt of gratitude to Stan for his steadfast devotion to Henry Schein and for bringing his unique blend of strategic vision, attention to detail, and entrepreneurship to the company,” Laskawy said.

More about Stanley M. Bergman’s tenure as CEO

Under Bergman, Henry Schein’s revenues increased from $225 million in 1989 to nearly $13 billion in 2024. That marked an approximate compound annual growth rate (CAGR) of 17.5%.

The company also completed an initial public offering (IPO) in 1995 and now has a market capitalization value of $9 billion.

Bergman took Henry Schein from a small, U.S.-based primarily dental mail order company to becoming a large global full-service dental distributor and a distributor of medical products to alternate care sites. The company said he created a fast-growing dental business and established Henry Schein as a global leader in advancing public-private partnership to support access to care for underserved individuals.

“It has been my greatest privilege to lead Team Schein over the past 35-plus years,” Bergman said. “Guided by our purpose-driven mission, we have built an agile company that is able to meet the changing needs of our customers, has created significant shareholder value, and is well positioned for the future.”

Filed Under: Business/Financial News, Dental, Featured Tagged With: Henry Schein, Personnel Moves

More recent news

  • Cambridge Heartwear inks £184M deal to supply NHS with portable ECG monitors
  • J&J, Smith+Nephew plans for ortho megamerger reportedly fall through
  • California and Massachusetts still reign as top US medtech headquarters locations
  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold
  • FDA clears Solventum’s combo wound care platform following Acera acquisition

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy